Literature DB >> 17313444

CTLA-4 regulates allergen response by modulating GATA-3 protein level per cell.

Francesca Nasta1, Silvia Corinti, Angela Bonura, Paolo Colombo, Gabriella Di Felice, Claudio Pioli.   

Abstract

T helper type 2 (Th2) cell differentiation requires the expression of GATA-3, a transcription factor that allows transcriptional activation of Th2 cytokine genes through chromatin remodelling. We investigated the role of the negative costimulatory receptor cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the regulation of GATA-3 expression, Th2 differentiation and immunoglobulin production during the immune response to allergens. BALB/c mice were immunized with a recombinant major allergenic component of Parietaria judaica pollen, rPar j I, and treated with blocking anti-CTLA-4 or control antibodies. Results showed that in vivo CTLA-4 blockade enhanced the Par j I-specific immunoglobulin E (IgE) serum level. In contrast, Par j I-specific IgG2a serum level was reduced, suggesting that CTLA-4 blockade skewed immunoglobulin production towards interleukin-4 (IL-4) -dependent immunoglobulin isotypes. Consistently, CTLA-4 blockade increased the frequency of Par j I-specific Th2 cells but not Th1 cells, as well as IL-4 and IL-5 but not interferon-gamma production. Our data also showed that CTLA-4 blockade enhanced the GATA-3 : T-bet messenger RNA ratio. Interestingly, in vivo CTLA-4 blockade did not increase the frequency of GATA-3 protein-expressing cells. In contrast, it enhances GATA-3 protein level per cell. Further, in vitro results show that the anti-CTLA-4 monoclonal antibody, by competing with CD80 for CTLA-4 binding, induced an enhancement in the frequency of IL-4-producing cells that correlates with the increase in GATA-3 protein level per cell. In conclusion, CTLA-4, by affecting the level of GATA-3 per cell, contributes to keeping this factor under the threshold required to become a Th2 effector cell. Consequently, it affects IgE/IgG2a production and contributes to the outcome of allergen-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313444      PMCID: PMC2265929          DOI: 10.1111/j.1365-2567.2007.02537.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism.

Authors:  W Ouyang; S H Ranganath; K Weindel; D Bhattacharya; T L Murphy; W C Sha; K M Murphy
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

2.  Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation.

Authors:  S Agarwal; A Rao
Journal:  Immunity       Date:  1998-12       Impact factor: 31.745

3.  The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells.

Authors:  W Zheng; R A Flavell
Journal:  Cell       Date:  1997-05-16       Impact factor: 41.582

4.  Cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibits CD28-induced IkappaBalpha degradation and RelA activation.

Authors:  C Pioli; L Gatta; D Frasca; G Doria
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

5.  Identification of an immunodominant IgE epitope of the Parietaria judaica major allergen.

Authors:  P Colombo; D Kennedy; T Ramsdale; M A Costa; G Duro; V Izzo; S Salvadori; R Guerrini; R Cocchiara; M G Mirisola; S Wood; D Geraci
Journal:  J Immunol       Date:  1998-03-15       Impact factor: 5.422

6.  Polarization of naive CD4+ T cells toward the Th1 subset by CTLA-4 costimulation.

Authors:  T Kato; H Nariuchi
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

7.  Interleukin-5-producing CD4+ T cells play a pivotal role in aeroallergen-induced eosinophilia, bronchial hyperreactivity, and lung damage in mice.

Authors:  S P Hogan; A Koskinen; K I Matthaei; I G Young; P S Foster
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

8.  Interleukin-13: central mediator of allergic asthma.

Authors:  M Wills-Karp; J Luyimbazi; X Xu; B Schofield; T Y Neben; C L Karp; D D Donaldson
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

9.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

10.  Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes.

Authors:  C M Cilio; M R Daws; A Malashicheva; C L Sentman; D Holmberg
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

View more
  4 in total

Review 1.  Application of the adverse outcome pathway (AOP) concept to structure the available in vivo and in vitro mechanistic data for allergic sensitization to food proteins.

Authors:  Jolanda H M van Bilsen; Edyta Sienkiewicz-Szłapka; Daniel Lozano-Ojalvo; Linette E M Willemsen; Celia M Antunes; Elena Molina; Joost J Smit; Barbara Wróblewska; Harry J Wichers; Edward F Knol; Gregory S Ladics; Raymond H H Pieters; Sandra Denery-Papini; Yvonne M Vissers; Simona L Bavaro; Colette Larré; Kitty C M Verhoeckx; Erwin L Roggen
Journal:  Clin Transl Allergy       Date:  2017-05-12       Impact factor: 5.871

2.  Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge.

Authors:  Lauren A Hirao; David A Hokey; Matthew P Morrow; Maria N Jure-Kunkel; David B Weiner
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

3.  Effects of PARP-1 deficiency on Th1 and Th2 cell differentiation.

Authors:  M Sambucci; F Laudisi; F Novelli; E Bennici; M M Rosado; C Pioli
Journal:  ScientificWorldJournal       Date:  2013-11-05

Review 4.  Immune-Modulating Perspectives for Low Frequency Electromagnetic Fields in Innate Immunity.

Authors:  Maria Manuela Rosado; Myrtill Simkó; Mats-Olof Mattsson; Claudio Pioli
Journal:  Front Public Health       Date:  2018-03-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.